APO Research
Talk to an analyst

APO RESEARCH · REPORT

GABAA Receptor Agonists

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global GABAA Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchGABAA Receptor Agonists Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal GABAA Receptor Agonists Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal GABAA Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GABAA Receptor Agonists Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal GABAA Receptor Agonists Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global GABAA Receptor Agonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for GABAA Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GABAA Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GABAA Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for GABAA Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GABAA Receptor Agonists include Takeda, Teva, Sun Pharma, Shanghai Pharmaceuticals Holding, Sandoz, Sanofi, Novartis, Mylan and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GABAA Receptor Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GABAA Receptor Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GABAA Receptor Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GABAA Receptor Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.

GABAA Receptor Agonists Segment by Company

Takeda

Teva

Sun Pharma

Shanghai Pharmaceuticals Holding

Sandoz

Sanofi

Novartis

Mylan

Roche

Pfizer

Huazhong Pharmaceutical

Sichuan HaiscoPharmaceuical

GSK

Fresenius Kabi

Changzhou Siyao Pharmaceutical

AstraZeneca

WG Critical Care

Viatris

Torrent Pharma

SAGE Therapeutics

Neurelis

Hikma

CHEPLAPHARM

Apotex

Akorn

GABAA Receptor Agonists Segment by Type

BZDs

Non-BZDs

GABAA Receptor Agonists Segment by Application

Epilepsy

Anxiety

Neuropathic Pain

Insomnia

Other

GABAA Receptor Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABAA Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GABAA Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABAA Receptor Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GABAA Receptor Agonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GABAA Receptor Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of GABAA Receptor Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of GABAA Receptor Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. GABAA Receptor Agonists Industry Trends Table 2. GABAA Receptor Agonists Industry Drivers Table 3. GABAA Receptor Agonists Industry Opportunities and Challenges Table 4. GABAA Receptor Agonists Industry Restraints Table 5. Global GABAA Receptor Agonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global GABAA Receptor Agonists Revenue Market Share by Manufacturers (2021-2026) Table 7. Global GABAA Receptor Agonists Sales by Manufacturers (k units) & (2021-2026) Table 8. Global GABAA Receptor Agonists Sales Market Share by Manufacturers Table 9. Global GABAA Receptor Agonists Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global GABAA Receptor Agonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global GABAA Receptor Agonists Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global GABAA Receptor Agonists Manufacturers, Product Type & Application Table 13. Global GABAA Receptor Agonists Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global GABAA Receptor Agonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of BZDs Table 17. Major Manufacturers of Non-BZDs Table 18. Global GABAA Receptor Agonists Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global GABAA Receptor Agonists Sales by Type (2021-2026) & (k units) Table 20. Global GABAA Receptor Agonists Sales by Type (2027-2032) & (k units) Table 21. Global GABAA Receptor Agonists Sales Market Share by Type (2021-2026) Table 22. Global GABAA Receptor Agonists Sales Market Share by Type (2027-2032) Table 23. Global GABAA Receptor Agonists Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global GABAA Receptor Agonists Revenue by Type (2021-2026) & (k units) Table 25. Global GABAA Receptor Agonists Revenue by Type (2027-2032) & (k units) Table 26. Global GABAA Receptor Agonists Revenue Market Share by Type (2021-2026) Table 27. Global GABAA Receptor Agonists Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Epilepsy Table 29. Major Manufacturers of Anxiety Table 30. Major Manufacturers of Neuropathic Pain Table 31. Major Manufacturers of Insomnia Table 32. Major Manufacturers of Other Table 33. Global GABAA Receptor Agonists Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global GABAA Receptor Agonists Sales by Application (2021-2026) & (k units) Table 35. Global GABAA Receptor Agonists Sales by Application (2027-2032) & (k units) Table 36. Global GABAA Receptor Agonists Sales Market Share by Application (2021-2026) Table 37. Global GABAA Receptor Agonists Sales Market Share by Application (2027-2032) Table 38. Global GABAA Receptor Agonists Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global GABAA Receptor Agonists Revenue by Application (2021-2026) & (k units) Table 40. Global GABAA Receptor Agonists Revenue by Application (2027-2032) & (k units) Table 41. Global GABAA Receptor Agonists Revenue Market Share by Application (2021-2026) Table 42. Global GABAA Receptor Agonists Revenue Market Share by Application (2027-2032) Table 43. Global GABAA Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global GABAA Receptor Agonists Sales by Region (2021-2026) & (k units) Table 45. Global GABAA Receptor Agonists Sales Market Share by Region (2021-2026) Table 46. Global GABAA Receptor Agonists Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global GABAA Receptor Agonists Sales Forecasted Market Share by Region (2027-2032) Table 48. North America GABAA Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 50. North America GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 51. Europe GABAA Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 53. Europe GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific GABAA Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa GABAA Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 60. Global GABAA Receptor Agonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global GABAA Receptor Agonists Revenue by Region (2021-2026) & (US$ Million) Table 62. Global GABAA Receptor Agonists Revenue by Region (2027-2032) & (US$ Million) Table 63. Global GABAA Receptor Agonists Revenue Market Share by Region (2021-2026) Table 64. Global GABAA Receptor Agonists Revenue Market Share by Region (2027-2032) Table 65. Takeda Company Information Table 66. Takeda Business Overview Table 67. Takeda GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Takeda GABAA Receptor Agonists Product Portfolio Table 69. Takeda Recent Development Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Teva GABAA Receptor Agonists Product Portfolio Table 74. Teva Recent Development Table 75. Sun Pharma Company Information Table 76. Sun Pharma Business Overview Table 77. Sun Pharma GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sun Pharma GABAA Receptor Agonists Product Portfolio Table 79. Sun Pharma Recent Development Table 80. Shanghai Pharmaceuticals Holding Company Information Table 81. Shanghai Pharmaceuticals Holding Business Overview Table 82. Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Product Portfolio Table 84. Shanghai Pharmaceuticals Holding Recent Development Table 85. Sandoz Company Information Table 86. Sandoz Business Overview Table 87. Sandoz GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sandoz GABAA Receptor Agonists Product Portfolio Table 89. Sandoz Recent Development Table 90. Sanofi Company Information Table 91. Sanofi Business Overview Table 92. Sanofi GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Sanofi GABAA Receptor Agonists Product Portfolio Table 94. Sanofi Recent Development Table 95. Novartis Company Information Table 96. Novartis Business Overview Table 97. Novartis GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Novartis GABAA Receptor Agonists Product Portfolio Table 99. Novartis Recent Development Table 100. Mylan Company Information Table 101. Mylan Business Overview Table 102. Mylan GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Mylan GABAA Receptor Agonists Product Portfolio Table 104. Mylan Recent Development Table 105. Roche Company Information Table 106. Roche Business Overview Table 107. Roche GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Roche GABAA Receptor Agonists Product Portfolio Table 109. Roche Recent Development Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Pfizer GABAA Receptor Agonists Product Portfolio Table 114. Pfizer Recent Development Table 115. Huazhong Pharmaceutical Company Information Table 116. Huazhong Pharmaceutical Business Overview Table 117. Huazhong Pharmaceutical GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Huazhong Pharmaceutical GABAA Receptor Agonists Product Portfolio Table 119. Huazhong Pharmaceutical Recent Development Table 120. Sichuan HaiscoPharmaceuical Company Information Table 121. Sichuan HaiscoPharmaceuical Business Overview Table 122. Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Product Portfolio Table 124. Sichuan HaiscoPharmaceuical Recent Development Table 125. GSK Company Information Table 126. GSK Business Overview Table 127. GSK GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. GSK GABAA Receptor Agonists Product Portfolio Table 129. GSK Recent Development Table 130. Fresenius Kabi Company Information Table 131. Fresenius Kabi Business Overview Table 132. Fresenius Kabi GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Fresenius Kabi GABAA Receptor Agonists Product Portfolio Table 134. Fresenius Kabi Recent Development Table 135. Changzhou Siyao Pharmaceutical Company Information Table 136. Changzhou Siyao Pharmaceutical Business Overview Table 137. Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Product Portfolio Table 139. Changzhou Siyao Pharmaceutical Recent Development Table 140. AstraZeneca Company Information Table 141. AstraZeneca Business Overview Table 142. AstraZeneca GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. AstraZeneca GABAA Receptor Agonists Product Portfolio Table 144. AstraZeneca Recent Development Table 145. WG Critical Care Company Information Table 146. WG Critical Care Business Overview Table 147. WG Critical Care GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. WG Critical Care GABAA Receptor Agonists Product Portfolio Table 149. WG Critical Care Recent Development Table 150. Viatris Company Information Table 151. Viatris Business Overview Table 152. Viatris GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Viatris GABAA Receptor Agonists Product Portfolio Table 154. Viatris Recent Development Table 155. Torrent Pharma Company Information Table 156. Torrent Pharma Business Overview Table 157. Torrent Pharma GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Torrent Pharma GABAA Receptor Agonists Product Portfolio Table 159. Torrent Pharma Recent Development Table 160. SAGE Therapeutics Company Information Table 161. SAGE Therapeutics Business Overview Table 162. SAGE Therapeutics GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. SAGE Therapeutics GABAA Receptor Agonists Product Portfolio Table 164. SAGE Therapeutics Recent Development Table 165. Neurelis Company Information Table 166. Neurelis Business Overview Table 167. Neurelis GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Neurelis GABAA Receptor Agonists Product Portfolio Table 169. Neurelis Recent Development Table 170. Hikma Company Information Table 171. Hikma Business Overview Table 172. Hikma GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Hikma GABAA Receptor Agonists Product Portfolio Table 174. Hikma Recent Development Table 175. CHEPLAPHARM Company Information Table 176. CHEPLAPHARM Business Overview Table 177. CHEPLAPHARM GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 178. CHEPLAPHARM GABAA Receptor Agonists Product Portfolio Table 179. CHEPLAPHARM Recent Development Table 180. Apotex Company Information Table 181. Apotex Business Overview Table 182. Apotex GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 183. Apotex GABAA Receptor Agonists Product Portfolio Table 184. Apotex Recent Development Table 185. Akorn Company Information Table 186. Akorn Business Overview Table 187. Akorn GABAA Receptor Agonists Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 188. Akorn GABAA Receptor Agonists Product Portfolio Table 189. Akorn Recent Development Table 190. Key Raw Materials Table 191. Raw Materials Key Suppliers Table 192. GABAA Receptor Agonists Distributors List Table 193. GABAA Receptor Agonists Customers List Table 194. Research Programs/Design for This Report Table 195. Authors List of This Report Table 196. Secondary Sources Table 197. Primary Sources List of Figures Figure 1. GABAA Receptor Agonists Product Image Figure 2. Global GABAA Receptor Agonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GABAA Receptor Agonists Market Size (2021-2032) & (US$ Million) Figure 4. Global GABAA Receptor Agonists Sales (2021-2032) & (k units) Figure 5. Global GABAA Receptor Agonists Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 GABAA Receptor Agonists Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. BZDs Image Figure 9. Non-BZDs Image Figure 10. Global GABAA Receptor Agonists Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global GABAA Receptor Agonists Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global GABAA Receptor Agonists Sales Market Share by Type (2021-2032) Figure 13. Global GABAA Receptor Agonists Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global GABAA Receptor Agonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global GABAA Receptor Agonists Revenue Market Share by Type (2021-2032) Figure 16. Epilepsy Image Figure 17. Anxiety Image Figure 18. Neuropathic Pain Image Figure 19. Insomnia Image Figure 20. Other Image Figure 21. Global GABAA Receptor Agonists Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global GABAA Receptor Agonists Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global GABAA Receptor Agonists Sales Market Share by Application (2021-2032) Figure 24. Global GABAA Receptor Agonists Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global GABAA Receptor Agonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global GABAA Receptor Agonists Revenue Market Share by Application (2021-2032) Figure 27. North America GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 29. U.S. GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 34. Germany GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 35. France GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 41. China GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 45. India GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa GABAA Receptor Agonists Sales Market Share by Country (2021-2032) Figure 49. Brazil GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile GABAA Receptor Agonists Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global GABAA Receptor Agonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global GABAA Receptor Agonists Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America GABAA Receptor Agonists Revenue (2021-2032) & (US$ Million) Figure 60. North America GABAA Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe GABAA Receptor Agonists Revenue (2021-2032) & (US$ Million) Figure 62. Europe GABAA Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific GABAA Receptor Agonists Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific GABAA Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa GABAA Receptor Agonists Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa GABAA Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. GABAA Receptor Agonists Value Chain Figure 68. Manufacturing Cost Structure Figure 69. GABAA Receptor Agonists Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • BZDs
  • Non-BZDs
Applications
  • Epilepsy
  • Anxiety
  • Neuropathic Pain
  • Insomnia
  • Other
Companies covered
  • Takeda
  • Teva
  • Sun Pharma
  • Shanghai Pharmaceuticals Holding
  • Sandoz
  • Sanofi
  • Novartis
  • Mylan
  • Roche
  • Pfizer
  • Huazhong Pharmaceutical
  • Sichuan HaiscoPharmaceuical
  • GSK
  • Fresenius Kabi
  • Changzhou Siyao Pharmaceutical
  • AstraZeneca
  • WG Critical Care
  • Viatris
  • Torrent Pharma
  • SAGE Therapeutics
  • Neurelis
  • Hikma
  • CHEPLAPHARM
  • Apotex
  • Akorn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GABAA Receptor Agonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GABAA Receptor Agonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global GABAA Receptor Agonists Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global GABAA Receptor Agonists Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global GABAA Receptor Agonists Market Dynamics
  1. 2.1 GABAA Receptor Agonists Industry Trends
  2. 2.2 GABAA Receptor Agonists Industry Drivers
  3. 2.3 GABAA Receptor Agonists Industry Opportunities and Challenges
  4. 2.4 GABAA Receptor Agonists Industry Restraints
3 GABAA Receptor Agonists Market by Manufacturers
  1. 3.1 Global GABAA Receptor Agonists Revenue by Manufacturers (2021-2026)
  2. 3.2 Global GABAA Receptor Agonists Sales by Manufacturers (2021-2026)
  3. 3.3 Global GABAA Receptor Agonists Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global GABAA Receptor Agonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GABAA Receptor Agonists Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global GABAA Receptor Agonists Manufacturers, Product Type & Application
  7. 3.7 Global GABAA Receptor Agonists Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GABAA Receptor Agonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GABAA Receptor Agonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GABAA Receptor Agonists Tier 1, Tier 2, and Tier 3
4 GABAA Receptor Agonists Market by Type
  1. 4.1 GABAA Receptor Agonists Type Introduction
  2. 4.1.1 BZDs
  3. 4.1.2 Non-BZDs
  4. 4.2 Global GABAA Receptor Agonists Sales by Type
  5. 4.2.1 Global GABAA Receptor Agonists Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GABAA Receptor Agonists Sales by Type (2021-2032)
  7. 4.2.3 Global GABAA Receptor Agonists Sales Market Share by Type (2021-2032)
  8. 4.3 Global GABAA Receptor Agonists Revenue by Type
  9. 4.3.1 Global GABAA Receptor Agonists Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GABAA Receptor Agonists Revenue by Type (2021-2032)
  11. 4.3.3 Global GABAA Receptor Agonists Revenue Market Share by Type (2021-2032)
5 GABAA Receptor Agonists Market by Application
  1. 5.1 GABAA Receptor Agonists Application Introduction
  2. 5.1.1 Epilepsy
  3. 5.1.2 Anxiety
  4. 5.1.3 Neuropathic Pain
  5. 5.1.4 Insomnia
  6. 5.1.5 Other
  7. 5.2 Global GABAA Receptor Agonists Sales by Application
  8. 5.2.1 Global GABAA Receptor Agonists Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global GABAA Receptor Agonists Sales by Application (2021-2032)
  10. 5.2.3 Global GABAA Receptor Agonists Sales Market Share by Application (2021-2032)
  11. 5.3 Global GABAA Receptor Agonists Revenue by Application
  12. 5.3.1 Global GABAA Receptor Agonists Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global GABAA Receptor Agonists Revenue by Application (2021-2032)
  14. 5.3.3 Global GABAA Receptor Agonists Revenue Market Share by Application (2021-2032)
6 Global GABAA Receptor Agonists Sales by Region
  1. 6.1 Global GABAA Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GABAA Receptor Agonists Sales by Region (2021-2032)
  3. 6.2.1 Global GABAA Receptor Agonists Sales by Region (2021-2026)
  4. 6.2.2 Global GABAA Receptor Agonists Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GABAA Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America GABAA Receptor Agonists Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe GABAA Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe GABAA Receptor Agonists Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific GABAA Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific GABAA Receptor Agonists Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa GABAA Receptor Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa GABAA Receptor Agonists Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global GABAA Receptor Agonists Revenue by Region
  1. 7.1 Global GABAA Receptor Agonists Revenue by Region
  2. 7.1.1 Global GABAA Receptor Agonists Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global GABAA Receptor Agonists Revenue by Region (2021-2026)
  4. 7.1.3 Global GABAA Receptor Agonists Revenue by Region (2027-2032)
  5. 7.1.4 Global GABAA Receptor Agonists Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America GABAA Receptor Agonists Revenue (2021-2032)
  8. 7.2.2 North America GABAA Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe GABAA Receptor Agonists Revenue (2021-2032)
  11. 7.3.2 Europe GABAA Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific GABAA Receptor Agonists Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific GABAA Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa GABAA Receptor Agonists Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa GABAA Receptor Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda GABAA Receptor Agonists Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva GABAA Receptor Agonists Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sun Pharma
  14. 8.3.1 Sun Pharma Company Information
  15. 8.3.2 Sun Pharma Business Overview
  16. 8.3.3 Sun Pharma GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharma GABAA Receptor Agonists Product Portfolio
  18. 8.3.5 Sun Pharma Recent Developments
  19. 8.4 Shanghai Pharmaceuticals Holding
  20. 8.4.1 Shanghai Pharmaceuticals Holding Company Information
  21. 8.4.2 Shanghai Pharmaceuticals Holding Business Overview
  22. 8.4.3 Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Product Portfolio
  24. 8.4.5 Shanghai Pharmaceuticals Holding Recent Developments
  25. 8.5 Sandoz
  26. 8.5.1 Sandoz Company Information
  27. 8.5.2 Sandoz Business Overview
  28. 8.5.3 Sandoz GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sandoz GABAA Receptor Agonists Product Portfolio
  30. 8.5.5 Sandoz Recent Developments
  31. 8.6 Sanofi
  32. 8.6.1 Sanofi Company Information
  33. 8.6.2 Sanofi Business Overview
  34. 8.6.3 Sanofi GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi GABAA Receptor Agonists Product Portfolio
  36. 8.6.5 Sanofi Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis GABAA Receptor Agonists Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mylan GABAA Receptor Agonists Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche GABAA Receptor Agonists Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer GABAA Receptor Agonists Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Huazhong Pharmaceutical
  62. 8.11.1 Huazhong Pharmaceutical Company Information
  63. 8.11.2 Huazhong Pharmaceutical Business Overview
  64. 8.11.3 Huazhong Pharmaceutical GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Huazhong Pharmaceutical GABAA Receptor Agonists Product Portfolio
  66. 8.11.5 Huazhong Pharmaceutical Recent Developments
  67. 8.12 Sichuan HaiscoPharmaceuical
  68. 8.12.1 Sichuan HaiscoPharmaceuical Company Information
  69. 8.12.2 Sichuan HaiscoPharmaceuical Business Overview
  70. 8.12.3 Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Product Portfolio
  72. 8.12.5 Sichuan HaiscoPharmaceuical Recent Developments
  73. 8.13 GSK
  74. 8.13.1 GSK Company Information
  75. 8.13.2 GSK Business Overview
  76. 8.13.3 GSK GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 GSK GABAA Receptor Agonists Product Portfolio
  78. 8.13.5 GSK Recent Developments
  79. 8.14 Fresenius Kabi
  80. 8.14.1 Fresenius Kabi Company Information
  81. 8.14.2 Fresenius Kabi Business Overview
  82. 8.14.3 Fresenius Kabi GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Fresenius Kabi GABAA Receptor Agonists Product Portfolio
  84. 8.14.5 Fresenius Kabi Recent Developments
  85. 8.15 Changzhou Siyao Pharmaceutical
  86. 8.15.1 Changzhou Siyao Pharmaceutical Company Information
  87. 8.15.2 Changzhou Siyao Pharmaceutical Business Overview
  88. 8.15.3 Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Product Portfolio
  90. 8.15.5 Changzhou Siyao Pharmaceutical Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca GABAA Receptor Agonists Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 WG Critical Care
  98. 8.17.1 WG Critical Care Company Information
  99. 8.17.2 WG Critical Care Business Overview
  100. 8.17.3 WG Critical Care GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 WG Critical Care GABAA Receptor Agonists Product Portfolio
  102. 8.17.5 WG Critical Care Recent Developments
  103. 8.18 Viatris
  104. 8.18.1 Viatris Company Information
  105. 8.18.2 Viatris Business Overview
  106. 8.18.3 Viatris GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Viatris GABAA Receptor Agonists Product Portfolio
  108. 8.18.5 Viatris Recent Developments
  109. 8.19 Torrent Pharma
  110. 8.19.1 Torrent Pharma Company Information
  111. 8.19.2 Torrent Pharma Business Overview
  112. 8.19.3 Torrent Pharma GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Torrent Pharma GABAA Receptor Agonists Product Portfolio
  114. 8.19.5 Torrent Pharma Recent Developments
  115. 8.20 SAGE Therapeutics
  116. 8.20.1 SAGE Therapeutics Company Information
  117. 8.20.2 SAGE Therapeutics Business Overview
  118. 8.20.3 SAGE Therapeutics GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 SAGE Therapeutics GABAA Receptor Agonists Product Portfolio
  120. 8.20.5 SAGE Therapeutics Recent Developments
  121. 8.21 Neurelis
  122. 8.21.1 Neurelis Company Information
  123. 8.21.2 Neurelis Business Overview
  124. 8.21.3 Neurelis GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Neurelis GABAA Receptor Agonists Product Portfolio
  126. 8.21.5 Neurelis Recent Developments
  127. 8.22 Hikma
  128. 8.22.1 Hikma Company Information
  129. 8.22.2 Hikma Business Overview
  130. 8.22.3 Hikma GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Hikma GABAA Receptor Agonists Product Portfolio
  132. 8.22.5 Hikma Recent Developments
  133. 8.23 CHEPLAPHARM
  134. 8.23.1 CHEPLAPHARM Company Information
  135. 8.23.2 CHEPLAPHARM Business Overview
  136. 8.23.3 CHEPLAPHARM GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 CHEPLAPHARM GABAA Receptor Agonists Product Portfolio
  138. 8.23.5 CHEPLAPHARM Recent Developments
  139. 8.24 Apotex
  140. 8.24.1 Apotex Company Information
  141. 8.24.2 Apotex Business Overview
  142. 8.24.3 Apotex GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Apotex GABAA Receptor Agonists Product Portfolio
  144. 8.24.5 Apotex Recent Developments
  145. 8.25 Akorn
  146. 8.25.1 Akorn Company Information
  147. 8.25.2 Akorn Business Overview
  148. 8.25.3 Akorn GABAA Receptor Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Akorn GABAA Receptor Agonists Product Portfolio
  150. 8.25.5 Akorn Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GABAA Receptor Agonists Value Chain Analysis
  2. 9.1.1 GABAA Receptor Agonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GABAA Receptor Agonists Production Mode & Process
  6. 9.2 GABAA Receptor Agonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GABAA Receptor Agonists Distributors
  9. 9.2.3 GABAA Receptor Agonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst